Guardant Health (GH)
(Delayed Data from NSDQ)
$21.40 USD
+0.79 (3.83%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $21.38 -0.02 (-0.09%) 7:06 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.40 USD
+0.79 (3.83%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $21.38 -0.02 (-0.09%) 7:06 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Zacks News
What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?
by Zacks Equity Research
In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.
What's in Store for Boston Scientific's (BSX) Q4 Earnings?
by Zacks Equity Research
On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.
After Plunging 27.6% in 4 Weeks, Here's Why the Trend Might Reverse for Guardant Health (GH)
by Zacks Equity Research
Guardant Health (GH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of -17.78% and 2.76%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Guardant Health (GH)
by Zacks Equity Research
Guardant Health (GH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of -10.34% and 8.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Bear of the Day: NeoGenomics (NEO)
by Kevin Cook
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
Earnings Preview: Guardant Health (GH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Exact Sciences (EXAS)
by Kevin Cook
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year
New Strong Sell Stocks for July 7th
by Zacks Equity Research
ACCD, DNLI, FSLY, FHB and GH have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2021.
J&J's (JNJ) Amivantamab Gets FDA Nod for Rare Lung Cancer
by Zacks Equity Research
With the FDA nod, J&J's (JNJ) Rybrevant becomes the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations.
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 40.24% and 5.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bear of the Day: Guardant Health (GH)
by Kevin Cook
Cancer detection innovator with liquid biopsy saw analysts slash estimates as R&D investment costs rise
New Strong Sell Stocks for March 29th
by Zacks Equity Research
HTHT, FNLPF, GMRE, THRY, and GH have been added to the Zacks Rank #5 (Strong Sell) List on March 29, 2021
New Strong Sell Stocks for March 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of -129.41% and 12.18%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Diagnostic and Genomic Stocks Storming Into October
by Kevin Cook
COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of -42.50% and 10.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
Will Guardant Health Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Guardant Health